Carre P C, Didier A P, Pipy B R, Forgue M F, Beraud M F, Meeus E P, Caratero A L, Leophonte P J
Service de Pneumologie et Allergologie, Hopital de Rangueil, Toulouse, France.
Am Rev Respir Dis. 1990 Nov;142(5):1068-72. doi: 10.1164/ajrccm/142.5.1068.
Pulmonary alveolar proteinosis is characterized by the accumulation of a lipoproteinaceous material within the alveoli of the lung. It is well established that patients with pulmonary alveolar proteinosis have a high incidence of complicating pulmonary infections possibly resulting from defects of antibacterial functions of alveolar macrophages. Moreover, for unclear reasons, an inflammatory response in the airways is frequently absent. In order to investigate the role of the lipoproteinaceous material in these two patterns, we tested the in vitro effects of a lavage fluid from a human pulmonary alveolar proteinosis on the secretion of reactive oxygen intermediates and arachidonic acid metabolites by normal guinea pig alveolar macrophages. After incubation with the lipoproteinaceous material, the luminol-enhanced chemiluminescence of zymosan-triggered alveolar macrophages was reduced in a dose-dependent fashion. The lipoproteinaceous material similarly reduced the chemiluminescence response in a cell-free xanthine-xanthine oxidase system generating superoxide anions. This latter observation suggests that the lipoproteinaceous material acts as a scavenger for superoxide anions produced by alveolar macrophages. Its purified protein or phospholipid fractions also resulted in a general inhibition of the secretion of arachidonic acid metabolites by alveolar macrophages challenged in vitro with zymosan. Our results suggest that the alveolar filling material of pulmonary alveolar proteinosis may inhibit the action of antibacterial and/or proinflammatory agents produced by alveolar macrophages. We speculate that such effects of the lipoproteinaceous material may play a role in vivo in the high incidence of pulmonary infections and in the absence of discernible interstitial or intraalveolar inflammation seen in pulmonary alveolar proteinosis.
肺泡蛋白沉积症的特征是肺内肺泡中积聚脂蛋白物质。众所周知,肺泡蛋白沉积症患者发生肺部感染并发症的几率很高,这可能是由于肺泡巨噬细胞抗菌功能缺陷所致。此外,原因不明的是,气道中常常没有炎症反应。为了研究脂蛋白物质在这两种情况中的作用,我们测试了来自一名人类肺泡蛋白沉积症患者的灌洗液对正常豚鼠肺泡巨噬细胞活性氧中间体和花生四烯酸代谢产物分泌的体外影响。与脂蛋白物质孵育后,酵母聚糖触发的肺泡巨噬细胞的鲁米诺增强化学发光以剂量依赖方式降低。脂蛋白物质同样降低了在产生超氧阴离子的无细胞黄嘌呤 - 黄嘌呤氧化酶系统中的化学发光反应。后一观察结果表明,脂蛋白物质可作为肺泡巨噬细胞产生的超氧阴离子的清除剂。其纯化的蛋白质或磷脂部分也导致体外受酵母聚糖刺激的肺泡巨噬细胞花生四烯酸代谢产物分泌普遍受到抑制。我们的结果表明,肺泡蛋白沉积症的肺泡填充物质可能抑制肺泡巨噬细胞产生的抗菌和/或促炎剂的作用。我们推测,脂蛋白物质的这种作用可能在体内对肺泡蛋白沉积症中肺部感染的高发生率以及未见明显的间质或肺泡内炎症起作用。